p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4338-4345

  Magro, Pellegrino G ^a,b   Russo, Angelo J ^a,b   Li, Wei Wei ^b   Banerjee, Debabrata ^c   Bertino, Joseph R ^c,d  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COMPLEMENTARY DNA; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; MESSENGER RNA; METHOTREXATE; PHOSPHOTRANSFERASE; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P53; RALTITREXED; THYMIDINE; THYMIDYLATE KINASE; THYMIDYLATE SYNTHASE; TRIMETREXATE; UNCLASSIFIED DRUG; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CHROMOSOME 9P; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROSARCOMA; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; TUMOR GROWTH; WESTERN BLOTTING; BIOSYNTHESIS; CANCER STEM CELL; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYME STABILITY; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME STABILITY; FIBROSARCOMA; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; QUINAZOLINES; TETRAHYDROFOLATE DEHYDROGENASE; THIOPHENES; THYMIDINE; THYMIDYLATE SYNTHASE; TRIMETREXATE; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042565963     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1045     Document Type: Article

References (39)

1. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
2. Ruas M, Peters G. The p161NK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
3. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999;9:22-30.
4. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
5. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14.
6. ARF links the tumour suppressors RB and p53. Nature 1998;395:124-5.
7. de Stanchina E, McCurrach ME, Zindy F, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998;12:2434-42.
8. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998;395:125-6.
9. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-33.
10. Weber JD, Jeffers JR, Rehg JE, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000;14:2358-65.
11. Sanchez-Cespedes M, Reed AL, Buta M, et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 1999;18:5843-9.
12. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
13. Eymin B, Karayan L, Seite P, et al. Human ARF binds E2FI and inhibits its transcriptional activity. Oncogene 2001;20:1033-41.
14. Martelli F, Hamilton T, Silver DP, et al. p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001;98:4455-60.
15. Mason SL, Loughran O, La Thangue NB. p14(ARF) regulates E2F activity. Oncogene 2002;21:4220-30.
16. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999;13:2670-7.
17. Deng X, Kim M, Vandier D, et al. Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin. Biochem Biophys Res Commun 2002;296:792-8.
18. Paulson TG, Almasan A, Brody LL, Wahl GM. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol 1998;18:3089-100.
19. Chen CY, Hall I, Lansing TJ, Gilmer TM, Tlsty TD, Kastan MB. Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L- aspartate. Cancer Res 1996;56:3659-62.
20. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7:2908-11.
21. Takebe N, Nakahara S, Zhao SC, et al. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors. Cancer Gene Ther 2000;7:910-9.
22. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994;8:2540-51.
23. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33.
24. Amer ES, Spasokoukotskaja T, Eriksson S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 1992;188:712-8.
25. Chang ZF, Huang DY. The regulation of thymidine kinase in HL-60 human promyeloleukemia cells. J Biol Chem 1993;268:1266-71.
26. Yalowich JC, Kalman TI. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem Pharmacol 1985;34:2319-24.
27. Rodenhuis S, McGuire JJ, Narayanan R, Bertino JR. Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 1986;46:6513-9.
28. Pogolotti AL Jr, Nolan PA, Santi DV. Methods for the complete analysis of 5-fluorouracil metabolites in cell extracts. Anal Biochem 1981;117:178-86.
29. Howell SB, Mansfield SJ, Taetle R. Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res 1981;41:945-50.
30. Howell SB, Mansfield SJ, Taetle R. Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate. Cancer Chemother Pharmacol 1981;5:221-6.
31. Taylor GA, Jackman AL, Calvert AH, Harrap KR. Plasma nucleoside and base levels following treatment with the new thymidylate synthetase inhibitor CB 3717. Adv Exp Med Biol 1984;165:379-82.
32. Li M, Zhao S, Banerjee D, Hantzopoulos P, Gilboa E, Bertino JR. Enhanced selectivity of methotrexate resistant CFU-GM colonies from transfected murine bone marrow in thymidine phosphorylase treated serum. Blood 1990;76(Suppl 1):938.
33. Bertino JR. Karnofsky memorial lecture: ode to methotrexate. J Clin Oncol 1993;11:5-14.
34. McGuire JJ, Mini E, Hsieh P, Bertino JR. Role of methotrexate polyglutamates in methotrexate- and sequential methotrexate-5-fluorouracil- mediated cell kill. Cancer Res 1985;45:6395-400.
35. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
36. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998;12:2984-91.
37. Guo-Chang F, Chu-Tse W. Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance. Cancer Lett 2000;158:203-10.
38. Domin BA, Grill SP, Bastow KF, Cheng YC. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells. Mol Pharmacol 1982;21:478-82.
39. Sobrero AF, Handschumacher RE, Bertino JR. Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2′-deoxyuridine. Cancer Res 1985;45:3161-3.